Lucius LuciPirfe Pirfenidone 200mg

Product Information

• Product name: LuciPirfe Pirfenidone 200mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Pirfenidone
• Current strength: 200mg
• SKU: LU-ITEM-87
• Site category: pulmonary fibrosis, other cancer

Product Summary

LuciPirfe Pirfenidone 200mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Pirfenidone is the active ingredient used for this product page. Public prescribing information for Pirfenidone was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

The mechanism of action of Pirfenidone in the treatment of IPF has not been established.

Reference Indications

Pirfenidone capsules are indicated for the treatment of idiopathic pulmonary fibrosis (IPF). Pirfenidone is a pyridone indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Reference Dosage and Administration

Recommended dosage: 801 mg three times daily (2,403 mg/day). Take with food.

With this 200mg product, that corresponds to 4 x 200mg tablets when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Elevated liver enzymes and drug-induced liver injury: ALT, AST, and bilirubin elevations have occurred with Pirfenidone including cases of drug-induced liver injury. Monitor ALT, AST, and bilirubin before and during treatment. Temporary dosage reductions or discontinuations may be required. ( 2.1 , 5.1 ) Photosensitivity and rash: Photosensitivity and rash have been noted with Pirfenidone. Avoid exposure to sunlight and sunlamps. Wear sunscreen and protective clothing daily. Temporary dosage reductions or discontinuations may be required. Interrupt Pirfenidone in case of signs or symptoms of SCAR. Permanently discontinue Pirfenidone if a SCAR is confirmed. Gastrointestinal disorders: Nausea, vomiting, diarrhea, dyspepsia, gastro-esophageal reflux disease, and abdominal pain have occurred with Pirfenidone.

Common Adverse Reactions and Monitoring

The safety of Pirfenidone has been evaluated in more than 1,400 subjects with over 170 subjects exposed to Pirfenidone for more than 5 years in clinical trials. Pirfenidone was studied in 3 randomized, double-blind, placebo-controlled trials (Studies 1, 2, and 3) in which a total of 623 patients received 2,403 mg/day of Pirfenidone and 624 patients received placebo. Subjects ages ranged from 40 to 80 years (mean age of 67 years). Most patients were male (74%) and Caucasian (95%). The mean duration of exposure to Pirfenidone was 62 weeks (range: 2 to 118 weeks) in these 3 trials.

Drug Interactions and Special Populations

Moderate (e.g., ciprofloxacin) and strong inhibitors of CYP1A2 (e.g., fluvoxamine) increase systemic exposure of Pirfenidone and may alter the adverse reaction profile of Pirfenidone. Discontinue fluvoxamine prior to administration of Pirfenidone or reduce to 267 mg three times a day. Consider dosage reduction with use of ciprofloxacin. Strong CYP1A2 Inhibitors The concomitant administration of Pirfenidone and fluvoxamine or other strong CYP1A2 inhibitors (e.g., enoxacin) is not recommended because it significantly increases exposure to Pirfenidone . Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of Pirfenidone and avoided during Pirfenidone treatment.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Pirfenidone public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.